Friday, December 15, 2017 10:28:44 PM
This inventory debt is the GOOD kind of debt, because it makes money. They can pay it off as they sell the games. it revolves... It is also calculated using the WHOLESALE price that Snakes pays. It does not include their markup/profit. So its worth millions in profits when sold... again, this is the GOOD kind of debt. It demonstrates their financial strength. It takes $, to make more $$$, right? The CEO of SN#N would never be given this level of credit/trust, not with BKs, foreclosures and fraud... AMFE is the exact opposite
AMFE's other debts are mostly low interest and/or short term loans that are being paid back with profits and some shares... They rarely dilute, but even if they had to, they could wipe the non-inventory related debts off the books with only a minor amount of shares at this and higher valuations, but there is no hurry. They appear to be managing it well. Cash is flowing in STRONG. AMFE is NET profitable... and their growth is accelerating BEFORE several major initiatives have even kicked in. Plus, overhead costs will reduce now that Midtown is making $$$... i could go on and on..
From what i understand, the Franchise Promissory Notes are actually payments from 2 Franchisees ($125K/each), to secure locations. It counts as debt now because AMFE has not fulfilled their half of the deal yet and would lose it if they dont. I could be wrong, but thats the way i think it works...
This story is as easy to read as any that you will find in pennyland... There is REAL Billion dollar valuation potential here. Do the DD, do the simple math. Most pennies are not this healthy at these early stages, while investing heavy in expansion...
My messages contain many opinions. Please do your own research
and validation.
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM